Cargando…

Investigation of Potential Drug–Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis

BACKGROUND: Methotrexate is frequently used to treat rheumatoid arthritis. Peficitinib (ASP015K; Smyraf(®)), an oral Janus kinase inhibitor indicated for the treatment of rheumatoid arthritis, may be coadministered with methotrexate. OBJECTIVE: The objective of this study was to investigate potentia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Tong, Moy, Selina, Valluri, Udaya, Cao, Ying, Zhang, Wenhui, Sawamoto, Taiji, Chindalore, Vishala, Akinlade, Bola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452880/ https://www.ncbi.nlm.nih.gov/pubmed/32591978 http://dx.doi.org/10.1007/s40261-020-00937-z

Ejemplares similares

Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects
por: Shibata, Mai, et al.
Publicado: (2020)

Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects
por: Gao, Xin, et al.
Publicado: (2022)

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan
por: Takeuchi, Tsutomu, et al.
Publicado: (2021)

Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
por: Takeuchi, Tsutomu, et al.
Publicado: (2020)

Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
por: Takeuchi, Tsutomu, et al.
Publicado: (2020)

Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function
por: Miyatake, Daisuke, et al.
Publicado: (2019)

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function
por: Miyatake, Daisuke, et al.
Publicado: (2019)

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib
por: Diller, Magnus, et al.
Publicado: (2019)

Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis
por: Toyoshima, Junko, et al.
Publicado: (2020)

Exposure–response modeling of peficitinib efficacy in patients with rheumatoid arthritis
por: Toyoshima, Junko, et al.
Publicado: (2021)

Efficacy of peficitinib in two patients with rheumatoid arthritis on maintenance hemodialysis
por: Nishimura, Akito, et al.
Publicado: (2022)

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
por: Takeuchi, Tsutomu, et al.
Publicado: (2016)

Peficitinib Inhibits the Chemotactic Activity of Monocytes via Proinflammatory Cytokine Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
por: Ikari, Yuzo, et al.
Publicado: (2019)

The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two‐Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers
por: Shibata, Mai, et al.
Publicado: (2020)

Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis
por: Okada, Morihiro, et al.
Publicado: (2017)

Targeted drug delivery of Methotrexate in situ gels for the treatment of Rheumatoid Arthritis
por: Venkatesh, Madhugiri Prakash, et al.
Publicado: (2020)

Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study
por: Genovese, Mark C., et al.
Publicado: (2019)

Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis
por: Patanè, Marinella, et al.
Publicado: (2013)

Nano Methotrexate versus Methotrexate in Targeting Rheumatoid Arthritis
por: Salem, Heba F., et al.
Publicado: (2022)

A drug–drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers
por: Shibata, Mai, et al.
Publicado: (2020)

Methotrexate alone and methotrexate combined with etanercept in treatment of rheumatoid arthritis
por: Rexhepi, Sylejman, et al.
Publicado: (2012)

Methotrexate Hepatotoxicity in Patients with Rheumatoid Arthritis
por: Sotoudehmanesh, R, et al.
Publicado: (2010)

Adherence to Methotrexate therapy in Rheumatoid Arthritis
por: Arshad, Nasim, et al.
Publicado: (2016)

MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments
por: Scheerens, Heleen, et al.
Publicado: (2011)

Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis
por: Bulatović Ćalasan, Maja, et al.
Publicado: (2013)

TRU-015, a small modular immunopharmaceutical (SMIP™) drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis
por: Burge, DJ, et al.
Publicado: (2007)

Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
por: Chen, Hsin-Hua, et al.
Publicado: (2016)

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
por: Fleischmann, Roy, et al.
Publicado: (2017)

Polymeric Nanoscale Drug Carriers Mediate the Delivery of Methotrexate for Developing Therapeutic Interventions Against Cancer and Rheumatoid Arthritis
por: Yu, Wen-Jun, et al.
Publicado: (2020)

Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis
por: Huang, Yinan, et al.
Publicado: (2023)

A pH-Responsive DNA Tetrahedron/Methotrexate Drug Delivery System Used for Rheumatoid Arthritis Treatment
por: Jin, Yi, et al.
Publicado: (2023)

Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis
por: Bello, Alfonso E, et al.
Publicado: (2017)

Safety Profile of Methotrexate Therapy in Patients With Rheumatoid Arthritis
por: Mustafa, Syed Hassan, et al.
Publicado: (2022)

Rheumatoid arthritis and Hailey‐Hailey disease treated with methotrexate
por: Mestre, Beatriz, et al.
Publicado: (2022)

Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage
por: Gallo, G, et al.
Publicado: (2016)

Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis
por: Hazlewood, Glen S, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1v9isoc0imus4935mgs8ovt3em